Illustrations in This Book	iv
PSAP-VII Editorial Board	v
Welcome	vi
Faculty Potential COI Disclosure	vii
Role of ACCP	vii
Role of BPS	vii
CPE AND PROGRAM INSTRUCTIONS	viii
Posttest Instructions	viii

Chronic Illnesses I	1
Chronic Illnesses I Panel	3
Chronic Illnesses I Subscriber Evaluation	5

## **Chronic Heart Failure**

By Jo Ellen Rodgers, Pharm.D., FCCP, BCPS; and Kristen Bova Campbell, Pharm.D., BCPS

Introduction	
Heart Failure Caused by Reduced Ejection Fraction	8
Standard Pharmacologic Therapy	8
Alternative/Adjunctive Pharmacologic	
Therapy for Select Patients	8
Nonpharmacologic Therapy	11
Heart Failure with Preserved Ejection Fraction	11
Therapy Goals	
Pharmacologic Therapy	11
Concomitant Diseases	12
Hypertension	
Atrial Fibrillation	12
Diabetes Mellitus	13
Chronic Kidney Disease	14
Adjusted Dosing in DM and/or CKD	
Chronic Obstructive Pulmonary Disease	15
Role of the Pharmacist	16
Pharmacist Intervention Trials	16
Disease Management Programs	16
Reimbursement	
Monitoring	17
Monitoring Response to Therapy	17
Patient Self-Care	17
Parameters for Hospitalization and Discharge	17
Additional Therapeutic Considerations	
Alternative Medicines and Supplements	
Vasopressin Antagonists	18
Conclusion	18
Annotated Bibliography	19
Self-Assessment Questions	23

#### **ANTICOAGULATION IN CHILDREN**

By Kathryn Timberlake, Pharm.D.; and Leonardo R. Brandao, M.D., MSc

Thromboembolism in Pediatric Patients	
Age-Specific Risk Factors/Etiology	
Neonates	
Infants	
Children	
Adolescents	
Clinical Manifestations and Consequences	29
Postthrombotic Syndrome	
Recurrent VTE	
Mortality	
Age-Specific Clinical Manifestations	
and Consequences	30
Pharmacotherapy	31
Unfractionated Heparin	
Low-Molecular-Weight Heparins	
Vitamin K Antagonists	
Antiplatelet Agents	35
Recombinant Tissue Plasminogen Activator	36
Specific Treatment	36
VTE Prophylaxis	36
Systemic-to-Pulmonary Arterial Shunts	
Kawasaki Disease	36
PE in Adolescents	37
Primary Prevention with Mechanical Heart Valves	
Role of the Pharmacist	37
Patient Education	37
Administration Difficulties	
Monitoring and Dose Adjustment	
Conclusion	
Annotated Bibliography	38
Self-Assessment Questions	45

### WARFARIN PHARMACOGENETICS

By Jaekyu Shin, Pharm.D., M.S., BCPS; and Larisa H. Cavallari, Pharm.D., FCCP, BCPS

Introduction
Background on Pharmacogenetics/
Pharmacogenomics
Challenges of Warfarin Therapy
CYP2C9 Polymorphisms
CYP2C9 Genotype, Warfarin Dose Variability,
and Allele Frequency by Race54
CYP2C9 and Risk of Adverse Reactions to Warfarin54

CYP2C9 and Time to Reach Stable Warfarin Dosing55
Clinical Implications of CYP2C9 Genotype55
VKORC1 Polymorphisms55
VKORC1 Genotype, Warfarin Dose Variability,
and Allele Frequency by Race56
VKORC1 and Risk of Adverse
Reactions to Warfarin56
VKORC1 and Time to Reach Stable
Warfarin Dosing56
Clinical Implications of the VKORC1 Genotype56
Other Genes
CYP4F2
Additional Genes of Interest for African Americans56
Regulatory Stance on Warfarin Pharmacogenetics57
Warfarin Pharmacogenetic Tests
Warfarin Pharmacogenetic Dosing Algorithms57
Clinical vs. Pharmacogenetic Warfarin
Dosing Algorithms
Evaluation of Warfarin Pharmacogenetic Tests
Role of the Pharmacist61
Conclusion
Annotated Bibliography61
Self-Assessment Questions

Chronic Illnesses II	
Chronic Illnesses II Panel	73
Chronic Illnesses II Subscriber Evaluation	

# New Technologies for Managing Diabetes Mellitus

### By Lisa B. Cohen, Pharm.D., CDE

Introduction	
Insulin Delivery Devices	77
Subcutaneous Injection Ports	
Insulin Pumps	
Insulin Pen Devices	81
Novel Insulin Delivery Technologies	
Blood Glucose Concentration Monitoring	
BG Monitors	
Accuracy	
Novel Whole BG Monitors	
Continuous Glucose Monitoring Systems	
Lancet Devices	
Future Technologies	
Hemoglobin A1C Testing	
Fructosamine Testing	
Technology Treatments	
Insulin-like Growth Factor 1	
Invasive Technology	
Predictive Modeling	
Software Technology	
Long-term Complications of DM and	
Treatment Technologies	89

Gastroparesis Treatment	89
Telemedicine for DM Retinopathy Screening	89
Monofilament/Sensory Testing	
Maggot Therapy for Wound Healing	
Telemedicine	
Decision-Support Software	90
Home Telehealth	90
Conclusion	
Annotated Bibliography	91
Self-Assessment Questions	95

### New Guidelines, Recommendations, Warnings, and Drugs for Diabetes Mellitus

*By Patricia R. Wigle, Pharm.D., BCPS; and Christopher Bernheisel, M.D.* 

Introduction	
The AACE/ACE Consensus Statement	
Hemoglobin A1C	
Treatment Approaches Based on Hemoglobin A	1C
	102
Insulin Therapy	
Discussion	
The ADA/EASD Consensus Algorithm	
Glycemic Goals of Therapy	
Tiered Interventions	
ADA Clinical Practice Recommendations	
Hemoglobin A1C as a Diagnostic Tool	
Aspirin Therapy	
New Concerns for Established Diabetes Drugs	
Exenatide	
Sitagliptin	
Thiazolidinediones	
Newer Diabetes Treatment Options	
DPP-4 Inhibitors	
GLP-1 Agonists	
Place in Therapy for Newer Agents	
Implications of Recent Clinical Trials	
Glycemic Control in Hospitalized Patients	
Gestational Diabetes Screening,	
Diagnosis, and Treatment	
Statin Use and Risk of Incident Diabetes	111
Role of the Pharmacist	
Conclusion	
Annotated Bibliography	
Self-Assessment Questions	

### Pharmacovigilance and FDA Drug Safety Policy

By Elaine H. Morrato, DrPH, MPH, CPH

Introduction	.119
The Premarketing Risk Assessment	.119

Primary Safety Aspects Addressed During
Drug Development
Size of the Premarketing Safety Database
Long-term Controlled Exposure
Diversity of Patient Exposure
Comparative Safety Data
The Postmarketing Risk Assessment
Passive Surveillance of Spontaneous
Adverse Event Reporting
Data Mining and Active Surveillance
Observational Pharmacoepidemiologic Studies124
Meta-analyses
Randomized Controlled Safety Trials
Determination of Causality
Recent Changes in U.S. Drug Safety
Policy and Practices
The Future of Drug Safety127
FDA Amendments Act of 2007127
Implications for the Practice of Clinical Pharmacy130
More Active Solicitation and Complete
Reporting of Suspected ADRs
More Comprehensive and Rigorous
Postmarketing Pharmacovigilance
Greater Transparency in Risk Evaluation
and Communication131
More Risk Mitigation132
Conclusion
Annotated Bibliography132
Self-Assessment Questions137

### **Skin Disorders**

By Teresa M. Bailey, Pharm.D., FCCP, BCPS; and Jodie L. Elder, Pharm.D., BCPS

Cutaneous Skin Reactions	145
Incidence and Risk Factors	145
Specific Cutaneous Skin Reactions	
Management of Cutaneous Skin Disorders	
Acne Vulgaris	
Incidence and Pathophysiology	
Acne Pharmacotherapy	153
Rosacea	
Introduction	
Rosacea Treatment	156
Conclusion	
Annotated Bibliography	157
Self-Assessment Questions	161

Chronic Illnesses III	165
Chonic Illnesses III Panel	167
Chronic Illnesses III Subscriber Evaluation	169

# PAIN MANAGEMENT IN PATIENTS WITH SUBSTANCE-USE DISORDERS

By Valerie Prince, Pharm.D., FAPhA, BCPS

Introduction	171
Epidemiology	171
Nomenclature	171
Pathophysiology	172
Pain	172
Addiction	173
Interface Between Addiction and Pain	173
Screening and Barriers	173
Identification of High-Risk Patients	173
Barriers to Care	174
Treatment Goals	174
Pain Management	174
Opioids	174
Nonsteroidal Anti-inflammatory Drugs	176
Antidepressants	176
Anticonvulsants	177
Anesthetics	177
Topical Agents	178
Muscle Relaxants	178
Interventional Injections/Blockade	178
Lifestyle and Physical Therapies	178
Management of Acute Pain in the Patient with	
Opioid Addiction	179
Patients on Opioid Replacement Therapy	179
Peri- and Postoperative Considerations	179
Nonopioid Alternatives for Perioperative Analgesia	
	180
Patient Education and Support Systems	181
Quality Improvement	181
Conclusion	182
Annotated Bibliography	182
Self-Assessment Questions	185

#### GLOMERULONEPHRITIS

By Sarah Tomasello, Pharm.D., BCPS

Introduction	
Incidence and Prevalence	
Pathophysiology	190
Histology	
Clinical Presentation and Evaluation	
Nephritic vs. Nephrotic Syndrome	
Complications of Nephrotic Syndrome	191
Types of GN	
IgA Nephropathy	
Minimal-Change Disease	
Lupus Nephritis	
Additional Considerations for Patients with GN	
Antimicrobial Prophylaxis	
Immunosuppressant Adverse Effects	
Role of the Pharmacist	
Annotated Bibliography	
Self-Assessment Questions	

# New Treatment Approaches for Gout

By Tricia M. Russell, Pharm.D., BCPS, CDE; and Kimberly Metka Welch, Pharm.D., BCPS

Introduction	
Risk Assessment	
Diagnosis Updates	
Treatment Updates	
Evidence-Based Guidelines	
Acute Therapy	
Chronic Therapy	
Adjunctive Therapy	
Emerging Therapy	
Quality Patient Care	
Practice Improvement	
Adherence	
Patient Education	
Role of the Pharmacist	
Annotated Bibliography	
Self-Assessment Questions	

#### Erythropoietin-Stimulating Agents in the Treatment of Anemia Associated with Chronic Kidney Disease and Cancer

By Bradley E. Hein, Pharm.D.; and Jane M. Pruemer, Pharm.D., FASHP, BCOP

Introduction
Anemia of CKD
Pathophysiology of Anemia of CKD
Role of Iron Therapy in the Treatment
of Anemia of CKD236
ESAs in the Treatment of Anemia in Patients
with CKD Not Treated with Dialysis
Review of Treatment Guidelines
Role of the Pharmacist240
Anemia of Cancer240
ESAs in Patients with Cancer
ESAs in the Treatment of Chemotherapy-
Induced Anemia241
Comparison of ESAs in Patients with Cancer
Advantages and Disadvantages of ESAs in
Patients with Cancer
Cost Comparison of ESAs in Patients with
CKD and Patients with Cancer
Adverse Reactions of ESAs in Patients with
CKD and Cancer243
Considerations for Patients not
Responding to ESA Therapy
Conclusion
Annotated Bibliography
Self-Assessment Questions
Reference Values for Common Laboratory Tests <sup>a</sup> 253